Business
Ascentage Pharma to Participate in Two Upcoming Investor Conferences in November 2025
ROCKVILLE, Md. and SUZHOU, China, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced today that the Company's management is scheduled to participate in the following investor conferences in November 202
About this update from Ascentage Pharma Group International
[{"type":"image","alt":"ASCENTAGE PHARMA GROUP INTERNATIONAL","displaySize":"","headline":null,"caption":"ASCENTAGE PHARMA GROUP INTERNATIONAL","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":113,"url":"https://media.zenfs.com/en/globenewswire.com/08e2ffb35cd6ca4b1993dc7253b2f226"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/_IJsL001nxkbUKUGjfvIgQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1ODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/08e2ffb35cd6ca4b1993dc7253b2f226","width":300,"height":113}},"lazy":false},{"type":"text","content":"ROCKVILLE, Md. and SUZHOU, China, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced today that the Company's management is scheduled to participate in the following investor conferences in November 2025.","length":506,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Goldman Sachs APAC Healthcare Corporate Day 2025: One-on-one and group investor meetings on November 5","length":102,"tagName":"p"}]},{"val":[{"type":"text","content":"Stifel 2025 Healthcare Conference: Presentation on November 13 at 2:40 pm EST","length":87,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":189,"olType":false},{"type":"text","content":"About Ascentage Pharma Group International","length":42,"tagName":"p"},{"type":"text","content":"Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”) is a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer. The company has built a rich pipeline of innovative drug products and candidates that include inhibitors targeting key apoptotic pathway proteins, such as Bcl-2, MDM2, p53 as well as next-generation kinase inhibitors.","length":524,"tagName":"p"},{"type":"text","content":"The Company’s first approved product, Olverembatinib, is the first novel third-generation BCR-ABL1 inhibitor approved in China for the treatment of patients w...